This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder
by Zacks Equity Research
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA
by Zacks Equity Research
AstraZeneca (AZN) gets the FDA's priority review status for its sNDA seeking label expansion of Farxiga for patients with heart failure with reduced ejection fraction.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $144.28, marking a -1.16% move from the previous day.
Pulmatrix Surges on License Agreement With Johnson & Johnson
by Zacks Equity Research
Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
by Zacks Equity Research
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
4 Reasons Why You Should Invest in J&J (JNJ) Stock in 2020
by Zacks Equity Research
Here are four reasons which investors may consider while investing in J&J's (JNJ) stock.
Will J&J be Able to Overcome Its Legal Troubles in 2020?
by Indrajit Bandyopadhyay
Here we discuss the growth potential of J&J's (JNJ) stock in 2020.
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck
Zacks.com featured highlights include: Johnson & Johnson, Gibraltar Industries, Omnicell, MDU Resources and Career Education
by Zacks Equity Research
Zacks.com featured highlights include: Johnson & Johnson, Gibraltar Industries, Omnicell, MDU Resources and Career Education
3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020
by Christopher Vargas
The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
Bet on These 5 Low Leverage Stocks to Invest Judiciously
by Zacks Equity Research
Debt level of a company is an important point of consideration while making an investment decision.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.93, marking a -0.35% move from the previous day.
GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA
by Zacks Equity Research
GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland
Pacira's Late-Stage Study on Exparel Label Expansion Positive
by Zacks Equity Research
Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.
Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Eli Lilly (LLY) and PNC Financial (PNC).
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $141.79, marking a +0.29% move from the previous day.
Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $139.99 in the latest trading session, marking a -0.36% move from the prior day.
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
by Zacks Equity Research
J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar
by Zacks Equity Research
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
by Kinjel Shah
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
J&J Stock Witnesses Volatility in '19: What to Expect in 2020
by Zacks Equity Research
Here we discuss the ups and downs of J&J's (JNJ) stock this year.